Posted by Michael Wonder on 24 May 2022
United Therapeutics announces FDA approval of Tyvaso DPI
24 May 2022 - First approval of a dry powder inhaler for treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
United Therapeutics announced today that the U.S. FDA has approved Tyvaso (treprostinil) dry powder inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
Tyvaso dry powder inhalation represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH and PH-ILD.
